|
|
||||||||
1Department of Health, Nutrition, and Exercise Sciences, and 2School of Nursing, University of Delaware; and 3Christiana Care Health System, Inc., Cardiovascular Research, Newark, Delaware
Submitted 22 February 2006 ; accepted in final form 7 June 2006
| ABSTRACT |
|---|
|
|
|---|
blood pressure; salt sensitivity; hypertension
Recently, Charkoudian et al. (3) infused hypertonic saline (3% NaCl) intravenously at two rates for 10 min each in humans and assessed muscle sympathetic outflow from the peroneal nerve, as well as baroreflex control of sympathetic outflow. Plasma osmolality and serum sodium concentration were modestly increased with this infusion protocol (osmolality increased
34 mosmol/kg). They found that baseline sympathetic outflow was not altered, but baroreflex control of sympathetic outflow was enhanced at the slow infusion rate but not the fast infusion rate. The lack of change in baseline sympathetic outflow during an osmotic stimulus in humans is important, because it is in contrast to what has been reported in the aforementioned animal literature, although, as noted above, the sympathetic responses are region specific. It could be that larger changes in osmolality must be elicited to observe the increase in sympathetic outflow.
We hypothesized that directly measured sympathetic outflow (peroneal microneurography) would increase during a progressive osmotic stimulus. To test this hypothesis, we had subjects complete a 60-min hypertonic saline (3% NaCl) trial. We (8) have recently demonstrated that this identical infusion protocol produces a robust
10 mosmol/kg increase in plasma osmolality, as well as an increase in mean arterial blood pressure. Because infusing hypertonic saline also causes volume expansion, we also had subjects complete an isotonic saline (0.9% NaCl) trial on a different day, permitting the comparison of a combined osmotic and volume stimulus (hypertonic saline infusion trial, HSI) to a volume-only stimulus (isotonic saline infusion trial, ISO).
| MATERIALS AND METHODS |
|---|
|
|
|---|
Screening visit. All subjects completed a medical history form and a physical activity readiness questionnaire. A baseline blood sample was obtained for a complete blood count, a lipid profile (i.e., total cholesterol, HDL-C, LDL-C, and triglycerides), fasting glucose, liver function (i.e., aspartate transaminase and alanine transaminase), kidney function (i.e., creatinine and blood urea nitrogen), and electrolytes (i.e., sodium, potassium, and chloride). Height and weight were measured (Healthometer scale, Continental Scale, Bridgeview, IL), and body mass index was calculated. To ensure that all subjects were healthy and had normal cardiovascular function, a resting and exercise 12-lead ECG were performed (Schiller AT-10, Electra-Med, Flint, MI). The exercise ECG was performed on an electronically braked cycle ergometer (Corival V2 Ergometer, Lode B.V. Medical Technology, The Netherlands). The initial workload was 75 W, with a 25-W increase every 2 min; all subjects achieved at least 85% of their age-predicted maximal heart rate (9). Resting and exercise blood pressures were manually assessed using a mercury sphygmomanometer and stethoscope. None of the subjects used tobacco products or were taking any medications.
Measurements. Heart rate was measured using a single lead electrocardiogram. Beat-by-beat blood pressure was assessed using a Finometer (Finometer, Finapres Medical Systems, The Netherlands). A cuff was placed on the left middle finger. The manufacturer's recommended calibrations were followed. Blood pressure values from the Finometer correlate very well with directly measured radial artery blood pressure (14). Systolic and diastolic blood pressure were also assessed using an automated oscillometric upper arm blood pressure cuff placed on the right arm (Dinamap Dash 2000, GE Medical Systems, Milwaukee, WI). Respiratory excursions were assessed with bands placed around the chest and stomach (Inductotrace System, Ambulatory Monitoring, Ardsley, NY).
Multiunit, postganglionic muscle sympathetic nerve activity was recorded using a tungsten microelectrode inserted into the peroneal nerve below the fibular head (18, 20). The raw signal was amplified, band-pass filtered, rectified, and integrated using a nerve traffic analyzer (model 662c-3, Nerve Traffic Analyzer, University of Iowa Bioengineering, Iowa City, IA).
Protocol.
Subjects were instructed to drink
1,800 ml of water the day before the experimental day (600 ml 3 times throughout the day). They were also instructed to avoid caffeine, alcohol, and exercise 12 h before the protocol. The woman was tested during the early follicular phase of their menstrual cycle. On the morning of the study, subjects were instructed to drink an additional 600 ml of water. Upon arriving at the lab (
0700 AM), subjects emptied their bladder, and the specific gravity of the urine was determined. A 20-gauge intravenous catheter was placed in a vein in the left and right antecubital area (the left intravenous catheter was used to infuse the saline solution, the right catheter for blood sampling). Subjects were randomized to receive either isotonic saline (0.9% NaCl) or hypertonic saline (3% NaCl) on their first experimental visit (Lifecare 5000 infusion pump, Abbott Laboratories, North Chicago, IL). They received the other solution on their subsequent visit, scheduled
1 mo after their first visit. The infusion rate was standardized at 0.15 ml·kg1·min1.
Five minutes of baseline data were collected and included the assessment of respiration, heart rate, beat-to-beat blood pressure, muscle sympathetic nerve activity, as well as a venous blood draw. To stabilize heart rate and blood pressure, a paced breathing protocol was utilized; all subjects were verbally cued from a recording to breath at 0.25 Hz (15 breaths/min) for the 5 min of baseline data. Compliance to the paced breathing protocol was visually confirmed. After baseline data collection, a 60-min infusion of either hypertonic or isotonic saline was started. Venous blood samples were obtained at 15, 30, 45, and 60 min. Five minutes of paced breathing commenced at 18, 33, and 50 min.
The whole blood collected throughout the infusion was transferred into the appropriate vacutainer tube and spun for 15 min at 2,500 rpm in a centrifuge (Allegra X-22R, Beckman Coulter, Fullerton, CA). The serum or plasma was pipetted off and used to determine serum sodium, potassium, chloride (EasyElectrolyte Analyzer, Medica, Bedford, MA) and plasma osmolality (model 3D3 Osmometer, Advanced Instruments, Norwood, MA). Quality control standards were run. For the determination of hematocrit, whole blood was transferred into precalibrated capillary tubes and spun rapidly on a Readacrit Centrifuge (Clay Adams Brand, Becton Dickinson, Parsippany, NJ). For the determination of plasma norepinephrine, whole blood was transferred into specially prepared and chilled EDTA-sodium metabisulfite vacutainers. These samples were spun at 2,500 rpm in a refrigerated centrifuge. The plasma was then pipetted off and promptly frozen in a 70°C freezer for future analysis by HPLC at the Mayo Medical Laboratories. The plasma norepinephrine was corrected for the infusion-induced increase in the plasma volume using the following formula:
![]() |
Data analysis. The respiratory, ECG, blood pressure, and muscle sympathetic nerve activity signals were collected at 500 Hz using Windaq recording software (DATAQ Instruments, Akron, OH). The ECG was peak detected, and blood pressure waveform peak and valley were detected (Windaq waveform browser, Advanced CODAS software). Each time point reported for heart rate, blood pressure, and muscle sympathetic nerve activity represents an average of 5 min of data. Muscle sympathetic nerve activity was analyzed using custom MatLab-based software (MatLab, The MathWorks, Natick, MA) (11). The signal was calibrated by assigning the peak voltage of a representative large burst the value of 1,000 and the voltage between bursts was assigned a value of zero.
Statistics. Data are expressed as means ± SE. A two-way repeated measures ANOVA (time and treatment; these are paired data) was used to test for treatment effects and interactions (SPSS 13.0). Post hoc comparisons were performed to compare the HSI and ISO at a given time point only when the ANOVA P value was <0.05 for a treatment effect or an interaction. Main effects of time are not reported, because the focus is on the HSI versus ISO comparisons. A P value of 0.05 or less was considered statistically significant.
| RESULTS |
|---|
|
|
|---|
As shown in Fig. 1, plasma osmolality increased during the HSI and remained stable during the ISO infusion (ANOVA, P < 0.01; post hoc analysis reported in Fig. 1). As expected, serum sodium concentrations paralleled the change in plasma osmolality during both infusions (data not shown). Hematocrit declined during both infusions (Fig. 1; ANOVA, P < 0.01).
|
|
|
|
|
| DISCUSSION |
|---|
|
|
|---|
With the infusion of hypertonic fluid, there is an expansion of the plasma volume. We attempted to isolate the effects of changes in peripheral osmolality by having an isotonic saline control condition. Volume expansion alone, acting through the baroreceptors, would be predicted to cause sympathoinhibition, as evidenced in human studies (5, 15) and animal studies (13). However, as observed in Fig. 1, hematocrit declined more during the HSI trial (ANOVA interaction, P < 0.01), suggesting that plasma volume expanded more during this trial, a finding that is not unexpected. If the infusion-induced expansion of the plasma volume were the only factor driving the sympathetic response, we would expect modest baroreflex-mediated inhibition of sympathetic outflow during the ISO infusion and robust inhibition of sympathetic outflow during the HSI. This is not the case in the present study, and the initial increase in muscle sympathetic outflow, despite a greater sympatho-inhibitory volume stimulus, suggests that increased osmolality influences sympathetic outflow. These data in humans are consistent with what has been reported in the animal literature (1, 6, 10, 16, 22), although the sympathetic response is region specific. An important unanswered question remains: why doesn't sympathetic outflow continue to increase in humans because the HSI utilized in the present study is a progressive osmotic stimulus?
We speculate that during an HSI the brain stem is presented with conflicting signals. That is, the volume load associated with this stimulus would act (through the baroreflex arc) to inhibit sympathetic outflow (13), and the osmotic stimulus [based on the supporting animal literature (2, 16, 19)] would act (through centrally located osmoreceptors) to increase sympathetic outflow. In normal healthy adults, these conflicting stimuli may result in a variable sympathetic response. That is, the early HSI-induced response is driven by the osmoreceptors, which subsequently become overwhelmed by the volume-induced sympathoinhibitory response. Thus, an intact baroreflex may modify the sympathetic response to an osmotic stimulus, which appears to be consistent with experimental findings in animals where the arterial baroreflex opposes the HSI-induced pressure increase (22). This is clearly speculative.
In a recent review paper, Brooks et al. (2) hypothesized that small dietary-induced increases in sodium chloride concentration may drive sympathetic outflow, and this sympathoexcitation may underlie salt-sensitive hypertension. Our data, along with the recent data by Charkoudian et al. (3) may have some relevance for this hypothesis. Charkoudian et al. (3) reported increased mean arterial pressure, and we report a trend toward differences in the systolic blood pressure response between the infusions (ANOVA, P = 0.08) and differences in pulse pressure. As stated, if the baroreflexes were the only operative mechanism, we would expect sympathetic inhibition in both studies. This was not the case in either study, and the failure to decrease sympathetic outflow in both studies [Chardoudian et al. (3) report no change, we report an initial increase in muscle sympathetic nerve activity] provides indirect evidence that another mechanism is operative, thereby supporting an osmoreceptor-sympathetic link in humans (2).
It is noteworthy that both our study and the study by Charkoudian et al. (3) utilized young, healthy adults; a population thought to be at the low end of the salt sensitivity of blood pressure continuum. Charkoudian et al. (3) reported an increase in the sensitivity of baroreflex control of muscle sympathetic outflow. Whereas increased sympathetic baroreflex control is often viewed from the perspective of protecting against hypotension, in the context of an acute salt loading protocol, it may also be important in buffering further sodium-induced increases in blood pressure (greater sympathetic inhibition with further increases in gain). In other words, the acute increase in gain reported by Charkoudian et al. could be an important mechanism defending against further and possibly excessive increases in blood pressure. Collectively, these data in humans support the conclusion that plasma osmolality may be an important afferent signal to the brain stem that influences both sympathetic baroreflex gain and basal sympathetic outflow.
When considering the issue of salt sensitivity, testing a group that has documented salt sensitivity would be informative. We speculate that true salt-sensitive individuals may demonstrate greater increases in sympathetic outflow for a given osmotic load or, alternately, may fail to acutely increase sympathetic baroreflex sensitivity. Either, or both, mechanism(s) could be an important factor underlying salt sensitivity of blood pressure in humans.
The plasma norepinephrine response differed between the HSI and ISO infusions (Fig. 3), supporting the conclusion that HSI-induced increases in plasma osmolality lead to sympathetic activation (with the limitation that we are not assessing production vs. clearance of norepinephrine). However, the time course between the muscle sympathetic responses and the plasma norepinephrine responses were different; this suggests that a change in circulating norepinephrine takes longer to develop. We examined the relationship between plasma norepinephrine and muscle sympathetic nerve activity at study onset. Others have demonstrated a relationship between these two values (12, 20, 21). We therefore ran a correlation between directly measured muscle sympathetic nerve activity and plasma norepinephrine at baseline (Fig. 4). The statistically significant correlation demonstrates that our two indexes of sympathetic outflow were in agreement at study onset, consistent with experimental data reported by others (12, 20, 21).
There are several limitations that should be mentioned. First, the volume stimulus was not matched precisely between the trials. A stronger study design would have been to more precisely match the volume stimulus between the two infusion trials, such that the decline in hematocrit would be similar. However, had we been able to do this, we can only guess that we would have observed greater sympathetic inhibition during the ISO trial. For example, Pawelczyk et al. (15), using a larger saline load, were able to nearly abolish spontaneous muscle sympathetic nerve activity. Thus, had we used a larger isotonic saline load, we would predict an even greater separation of responses between the HSI and ISO trials. Second, we did not assess arginine vasopressin concentration. It is well known that increasing osmolality in humans causes an increase in circulating arginine vasopressin (17). Importantly though, Scrogin et al. (16) concluded that in rats the relationship between osmolality and lumbar sympathetic activity is independent of vasopressin concentration. Third, it is unfortunate that we were not able to maintain the muscle sympathetic nerve recording for the duration of the study for all subjects. Recording from the peroneal nerve in humans is technically demanding, and slight movements can impair the signal-to-noise ratio.
We conclude that HSI-induced increases in plasma osmolality are associated with increases in efferent sympathetic outflow in humans. As shown with the HSI, there was an initial increase in sympathetic outflow. These data support the hypothesis that there is a relationship between plasma osmolality and sympathetic outflow in humans.
| GRANTS |
|---|
|
|
|---|
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
N. Charkoudian and J. A. Rabbitts Sympathetic Neural Mechanisms in Human Cardiovascular Health and Disease Mayo Clin. Proc., September 1, 2009; 84(9): 822 - 830. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-L. Fan, J. D. Cotter, R. A. I. Lucas, K. Thomas, L. Wilson, and P. N. Ainslie Human cardiorespiratory and cerebrovascular function during severe passive hyperthermia: effects of mild hypohydration J Appl Physiol, August 1, 2008; 105(2): 433 - 445. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Kolsen-Petersen, K. Bendtzen, and E. Tonnesen Infusion of hypertonic saline before elective hysterectomy: effects on cytokines and stress hormones Br. J. Anaesth., April 1, 2008; 100(4): 478 - 484. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Wenner, W. C. Rose, E. P. Delaney, M. E. Stillabower, and W. B. Farquhar Influence of plasma osmolality on baroreflex control of sympathetic activity Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2313 - H2319. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |